MASH with Liver Fibrosis: From Growing Burden to Targeted Treatment - report from UEG Week 2026

So we are here at UEG, United European Gastroenterology Congress, and it was a surprise for me that we have seen many lectures related to liver disease.

So this means that gastroenterologists are also opening to an unrecognized disease also in our digestive disease clinics.

And what we are seeing is that with screening pathways and referral pathways, we are diagnosing patients with this disease and identifying those ones that need treatment.

This is good news because nowadays we have two treatments available for the treatment of our patients.

These two treatments are GLP-1 or the so-called Resmetirone.

These two treatments are now FDA and EMA approved for the treatment of our patients.

And what should we do when we have a patient that needs treatment? And which of these two available drugs should we use? So I think, first of all, is that whatever drug you use, it will be good for the patient.

So sometimes we debate a lot what to do, but the patient is in front of us, and the patient is the one who will benefit.

This is number one.

Number two, it is true that a lot of these patients have many metabolic disorders associated and for the holistic treatment of this disease, the GLP-1 treatments can have some extra benefit.

Nevertheless, GLP-1 treatments are subcutaneous and some of my patients have commented that they do not like a lot the subcutaneous administration and it implies some adverse effects that are difficult to manage.

On the contrary, with resmetirone, we have a liver direct therapy.

And this is good because we, as pathologists, like what is really direct for the liver.

With resmeterone, this is an oral treatment with less side effects.

And what we really also know is that in the lipid profile, it has a dramatic decrease of not only lipids in the liver, but also lipids in our blood, LDL levels or lipoprotein A levels that correlate with dyslipidemia.

So, in summary, now we have two treatments.

Whatever treatment the patient receives, if it is more a holistic treatment from an endocrinology unit, or if it's more a liver-directed therapy from the pathology unit, my thoughts is that the patient will benefit, and this is the best of the objectives that we have in medicine.

So we are here at UEG, United European Gastroenterology Congress, and it was a surprise for me that we have seen many lectures related to liver disease.

So this means that gastroenterologists are also opening to an unrecognized disease also in our digestive disease clinics.

And what we are seeing is that with screening pathways and referral pathways, we are diagnosing patients with this disease and identifying those ones that need treatment.

This is good news because nowadays we have two treatments available for the treatment of our patients.

These two treatments are GLP-1 or the so-called Resmetirone.

These two treatments are now FDA and EMA approved for the treatment of our patients.

And what should we do when we have a patient that needs treatment? And which of these two available drugs should we use? So I think, first of all, is that whatever drug you use, it will be good for the patient.

So sometimes we debate a lot what to do, but the patient is in front of us, and the patient is the one who will benefit.

This is number one.

Number two, it is true that a lot of these patients have many metabolic disorders associated and for the holistic treatment of this disease, the GLP-1 treatments can have some extra benefit.

Nevertheless, GLP-1 treatments are subcutaneous and some of my patients have commented that they do not like a lot the subcutaneous administration and it implies some adverse effects that are difficult to manage.

On the contrary, with resmetirone, we have a liver direct therapy.

And this is good because we, as pathologists, like what is really direct for the liver.

With resmeterone, this is an oral treatment with less side effects.

And what we really also know is that in the lipid profile, it has a dramatic decrease of not only lipids in the liver, but also lipids in our blood, LDL levels or lipoprotein A levels that correlate with dyslipidemia.

So, in summary, now we have two treatments.

Whatever treatment the patient receives, if it is more a holistic treatment from an endocrinology unit, or if it's more a liver-directed therapy from the pathology unit, my thoughts is that the patient will benefit, and this is the best of the objectives that we have in medicine.